课题基金 / 基金详情

Gabapentin for Relapse Prevention: Alc. Withdrawal-Brain GABA/Glutamate Effects

Gabapentin for Relapse Prevention: Alc. Withdrawal-Brain GABA/Glutamate Effects
加巴喷丁预防复发:Alc。
批准号:
8696333
负责人:
RAYMOND F ANTON
金额:
$49.77万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-25 至 2018-07-31

项目摘要

项目成果

RAYMOND F ANTON的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):酒精依赖的药物治疗是有限的,具有证明疗效的药物显然不适用于每个人。在医学领域,存在对更个性化的治疗方法的极大期望和需求。为了实现这一值得称赞的目标,需要更好地匹配安全、负担得起、有效的新型药物,以适应酗酒者的临床和/或生物学亚组。一个未充分研究的酒精使用障碍亚组是那些经历酒精戒断(AW)综合征的人,这是一种明确的体征和症状,存在于大量突然停止饮酒的人中。我们在两项已完成并发表的临床试验中发现,加巴喷丁(一种研究充分且普遍使用的通用药物)先前在治疗急性AW方面显示出有效性,但在具有“AW病史”的患者中,在更长时间内也可能有效地预防复发。由于加巴喷丁在这些研究中与其他药物联合使用,并且给药持续时间相对较短(6周),因此有必要进行更长时间的前瞻性对照试验,以证明其在有AW病史的患者中单独使用时的疗效。基础科学研究假设,两个突出的神经化学系统,谷氨酸和GABA系统,失调的基础AW的表达,并可能被加巴喷丁修改。通过使用先进的磁共振成像技术(1H-MRS)来测量谷氨酸和GABA的脑水平,并通过对某些谷氨酸和GABA受体的功能变体进行基因分型,我们有机会探索这些系统在预测复发和加巴喷丁作用机制中的参与-为良好的临床试验提供重要的转化科学组成部分。 为此,将筛选190名患有酒精使用障碍的个体,在戒酒3-7天后,90名符合DSM-5标准的AW病史的个体将被随机分配到为期16周的加巴喷丁或安慰剂试验中。所有受试者将在治疗随机化前接受1H-MRS,并在治疗第17-24天之间再次接受1H-MRS,所有受试者将接受谷氨酸8受体和GABA 2A基因特异性变异的基因分型。将在16周内(以及治疗后第20周和第28周)对受试者的饮酒和其他显著结局变量进行评价。主要结局变量将是“重度饮酒日复发的受试者百分比”。脑谷氨酸和/或GABA水平的变化和遗传变异将分别作为治疗反应的介质或调节剂进行评价。积极的结果将提供另一种药物选择,同时推进一种更加个性化的酒精使用障碍药物治疗方法。此外,提供有关AW风险和治疗的大脑和遗传机制的新信息增加了科学价值。因此,在了解酒精依赖个体的生物学和治疗方面的进步将大大加强。
英文摘要
DESCRIPTION (provided by applicant): Pharmacotherapy of alcohol dependence is limited and the medications with proven efficacy clearly do not work for everyone. In the field of medicine, there is a great desire, and need, for more personalized treatment approaches. To achieve this laudable goal, there needs to be better matching of novel medications that are safe, affordable, and efficacious to clinical and/or biological subgroups of alcoholics. One understudied alcohol use disorder subgroup are those that experience alcohol withdrawal (AW) syndrome, a well-defined constellation of signs and symptoms present in a significant number of those who abruptly stop drinking. We have found in two completed and published clinical trials that gabapentin (a well-studied and ubiquitously prescribed generic medication), that had previously shown efficacy in treatment of acute AW, might also be efficacious in preventing relapse over a more prolonged period in those with a "history of AW". Since gabapentin was combined with other medications in those studies and given for a relatively short duration (six weeks), a longer prospective controlled trial is necessary to prove its efficacy when given alone, in those with an AW history. Basic science investigation postulates that dysregulation in two prominent neurochemical systems, the glutamate and GABA systems, underlies the expression of AW and may be modified by gabapentin. By using advanced magnetic resonance imaging technology (1H-MRS) to measure brain levels of glutamate and GABA, and by genotyping functional variants in certain glutamate and GABA receptors, we have the opportunity to explore the involvement of these systems in predicting relapse and in the mechanism of gabapentin action - providing an important translational science component to a well-conducted clinical trial. To that end, 190 individuals with alcohol use disorder will be screened, and after 3-7 days of abstinence 90 individuals, who meet DSM-5 criteria for a history of AW, will be randomized to a 16-week trial of gabapentin or placebo. All subjects will undergo 1H-MRS prior to treatment randomization and again between days 17-24 of treatment and all subjects will be genotyped for specific variation in glutamate 8 receptor and GABA2A genes. Subjects will be evaluated over 16 weeks (and post-treatment at weeks 20 and 28) for drinking and other salient outcome variables. The main outcome variable will be "percent of subjects relapsing to a heavy drinking day". Change in brain glutamate and/or GABA levels and genetic variants will be evaluated as mediators or moderators respectively of treatment-response. Positive results would provide another medication option, while advancing a more personalized approach to pharmacotherapy of alcohol use disorder. Also, providing new information on brain and genetic mechanisms underlying AW risk and treatment adds scientific value. As such, advancement in understanding the biology and treatment of individuals with alcohol dependence would be greatly enhanced.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Gabapentin for Relapse Prevention: Alc. Withdrawal-Brain GABA/Glutamate Effects
Gabapentin for Relapse Prevention: Alc. Withdrawal-Brain GABA/Glutamate Effects
Genetic and brain mechanisms of naltrexone's treatment efficacy for alcoholism
Genetic and brain mechanisms of naltrexone's treatment efficacy for alcoholism
海外基金